1. Home
  2. SKIL vs EQ Comparison

SKIL vs EQ Comparison

Compare SKIL & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skillsoft Corp.

SKIL

Skillsoft Corp.

HOLD

Current Price

$8.42

Market Cap

72.1M

Sector

Technology

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.10

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKIL
EQ
Founded
1998
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.1M
57.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SKIL
EQ
Price
$8.42
$1.10
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
343.6K
1.0M
Earning Date
12-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$515,774,000.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.65
$0.27
52 Week High
$34.43
$2.35

Technical Indicators

Market Signals
Indicator
SKIL
EQ
Relative Strength Index (RSI) 49.38 42.87
Support Level $7.72 $1.12
Resistance Level $10.00 $1.61
Average True Range (ATR) 0.90 0.19
MACD 0.26 -0.05
Stochastic Oscillator 48.20 4.58

Price Performance

Historical Comparison
SKIL
EQ

About SKIL Skillsoft Corp.

Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: